




The relative strengths and weaknesses of Rigel Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rigel Pharmaceuticals INC compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Rigel Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 10% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	119,005
Cost of Goods Sold	906
Intangible Assets	0
Liabilities, Current	58,212
Liabilities, Non-Current	0
Other Assets	26,405
Other Compr. Net Income	2,244
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	59,288
Property and Equipment	2,159
Research and Development	52,885
Selling, General and Administrative Expense	74,588

Output Variable	Value in 1000 USD
Assets	147,569
Liabilities	58,212
Expenses	128,379
Revenues	59,288
Stockholders Equity	89,357
Net Income	-69,091
Comprehensive Net Income	-67,969
BaseVar	197,846
ECR before Limited Liability	123%
Economic Capital Ratio	248%